Page 107 - Read Online

Ma et al. Hepatoma Res 2019;5:8 I http://dx.doi.org/10.20517/2394-5079.2018.104 Page 11 of 12

40. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from
different geographical locations. World J Gastroenterol 2015;21:311-7.
41. Lee SE, Chang SH, Kim WY, Lim SD, Kim WS, et al. Frequent somatic TERT promoter mutations and CTNNB1 mutations in
hepatocellular carcinoma. Oncotarget 2016;7:69267-75.
42. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, et al. High frequency of telomerase reverse-transcriptase promoter somatic
mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4:2218.
43. Huang W, Zhou W, Li C, Yang Y, Shang YK, et al. Promoter mutations and cellular distribution of telomerase in non-clear cell and
clear cell hepatocellular carcinoma. Oncotarget 2017;8:26288-97.
44. Yang XJ, Guo XC, Chen Y, Chen GR, Ma Y, et al. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated
hepatocellular carcinoma. Oncotarget 2016;7:27838-47.
45. Chen YL, Jeng YM, Chang CN, Lee HJ, Hsu HC, et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong
association with hepatitis C infection and absence of hepatitis B infection. Int J Surg 2014;12:659-65.
46. Yuan XT, Cheng GH, Yu JY, Zheng SZ, Sun C, et al. The TERT promoter mutation incidence is modified by germline TERT
rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Oncotarget 2017;8:23120-9.
47. Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, et al. Tumor specific mutations in TERT promoter and CTNNB1 gene in
hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget 2016;7:54253-62.
48. Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu; Cancer Genome Atlas Research Network.
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017;169:1327-41.e23.
49. Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, et al. Molecular scoring of hepatocellular carcinoma for predicting metastatic
recurrence and requirements of systemic chemotherapy. Cancers (Basel) 2018;10:E367.
50. Eichenmuller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, et al. The genomic landscape of hepatoblastoma and their progenies
with HCC-like features. J Hepatol 2014;61:1312-20.
51. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, et al. Whole-genome mutational landscape and characterization of noncoding
and structural mutations in liver cancer. Nat Genet 2016;48:500.
52. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, et al. Telomerase reverse transcriptase promoter mutation is an
early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology
2014;60:1983-92.
53. Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouze E, et al. Histological subtypes of hepatocellular carcinoma are related to
gene mutations and molecular tumour classification. J Hepatol 2017;67:727-38.
54. Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, et al. Telomerase reverse transcriptase germline mutations and
hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Med 2017;6:1930-40.
55. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
World J Gastroenterol 2014;20:12945-55.
56. Ki Kim S, Ueda Y, Hatano E, Kakiuchi N, Takeda H, et al. TERT promoter mutations and chromosome 8p loss are characteristic of
nonalcoholic fatty liver disease-related hepatocellular carcinoma. Int J Cancer 2016;139:2512-8.
57. Jiao J, Watt GP, Stevenson HL, Calderone TL, Fisher-Hoch SP, et al. Telomerase reverse transcriptase mutations in plasma DNA in
patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors. Hepatol Commun 2018;2:718-31.
58. Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, et al. The effects of hepatitis B virus integration into the genomes of
hepatocellular carcinoma patients. Genome Res 2012;22:593-601.
59. Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, et al. Landscape of DNA virus associations across human malignant cancers:
analysis of 3,775 cases using RNA-Seq. J Virol 2013;87:8916-26.
60. Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, et al. Hepatitis B virus-related insertional mutagenesis occurs
frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003;22:3911-6.
61. Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B
and hepatitis C infections. Oncotarget 2016;7:25087-102.
62. Kaslow DC, Black S, Bloom DE, Datla M, Salisbury D, et al. Vaccine candidates for poor nations are going to waste. Nature
2018;564:337-9.
63. Yang X, Wu L, Lin J, Wang A, Wan X, et al. Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent
normal liver tissue. Int J Cancer 2017;140:1324-30.
64. Ferber MJ, Montoya DP, Yu C, Aderca I, McGee A, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus
(HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003;22:3813-20.
65. Sung WK, Zheng H, Li S, Chen R, Liu X, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat
Genet 2012;44:765-9.
66. Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, et al. Identification of human cancer-related genes by naturally occurring
hepatitis B virus DNA tagging. Oncogene 2001;20:6233-40.
67. Ding D, Lou X, Hua D, Yu W, Li L, et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a
next-generation sequencing-based approach. PLoS Genet 2012;8:e1003065.
68. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, et al. Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44:760-4.
69. Li W, Zeng X, Lee NP, Liu X, Chen S, et al. HIVID: an efficient method to detect HBV integration using low coverage sequencing.
Genomics 2013;102:338-44.
70. Toh ST, Jin Y, Liu LZ, Wang JB, Babrzadeh F, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients
reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis 2013;34:787-98.